Check out this recent editor's pick:
Pain Treatment in the Companion Canine Model to Validate Rodent Results and Incentivize the Transition to Human Clinical Trials.
All site content, except where otherwise noted, is licensed under a Creative Commons BY-NC-ND License. Additional permissions for appropriate reuse available on request.
International Association for the Study of Pain
1510 H Street N.W., Suite 600
Washington, D.C. 20005-1020
The IASP Pain Research Forum is a production of the International Association for the Study of Pain
All site content, except where otherwise noted, is licensed under a Creative Commons BY-NC-ND License. Additional permissions for appropriate reuse available on request.
Comments
Michael Iadarola, Clinical Center
This review examines the
Editor's note: Michael Iadarola is a co-author of the above journal article.
This review examines the development and uses of a large animal model to improve translation of basic research to human clinical trials. Specifically, the companion canine model, developed and validated by co-author DCB, fills the gap between preclinical rodent models and human trials. We discuss how we have used it to evaluate a new treatment, resiniferatoxin (RTX), for cancer pain and osteoarthritis. RTX is now being developed as an interventional analgesic treatment for both human and animal pain problems. Also, we suggest ways that the companion canine model can be used to evaluate other drugs and provide information to support "go-no-go" decisions in the transition to human trials.